Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Q3 Trading Update

28 Oct 2021 07:00

RNS Number : 4938Q
Elementis PLC
28 October 2021
 

Elementis plc

Q3 Trading Update

Financial recovery continues

Outlook unchanged, in line with expectations

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 30 September 2021.

Third quarter business performance

 

The Group has delivered a strong third quarter performance as trading continues to improve with revenue up 16% on an underlying basis, driven by higher volumes and pricing actions. While there are material global supply chain challenges, such as raw material availability, logistical bottlenecks and rising inflation, we are successfully managing these impacts via supply resiliency, self-help actions and the implementation of price increases. As a result, our 2021 outlook is unchanged.

 

· Coatings continued to perform well with strong revenue growth versus the prior year period, as robust industrial coatings activity more than offset a moderation in European decorative demand. Despite cost inflation headwinds, the combination of pricing actions and continued growth will keep the business on track for improved operating margins versus the prior year.

 

· Personal Care performance improved on the prior year period as demand continued to show signs of recovery from COVID-19 lows, particularly in cosmetics, as social and travel restrictions began to ease, albeit still at levels below 2019. As expected, the new AP Actives plant in India started up in Q3 and a 12 month ramp up is now in progress.

 

· Talc revenue rose modestly on the prior year period as semi-conductor related supply challenges significantly reduced global automotive production. Pricing actions and cost savings, in response to increased logistics and energy costs, are expected to support a sequentially improved second half performance.

· Chromium performance improved on the prior year, as demand strengthened in areas such as aerospace and refractory. Global industry utilisation levels continued to improve and, if sustained, should result in improved pricing in 2022.

 

We have continued to successfully deliver against our Innovation, Growth and Efficiency strategy. In 2021 we expect to launch over 20 new products, win more than $35m of new business, and deliver $10m of in year cost savings.

Outlook

 

The full year outlook remains unchanged; the Group expects to deliver an improved financial performance and a reduction in leverage, in line with expectations.

 

The second half of the year is expected to follow a normal level of seasonality, with continued demand recovery and self-help actions mitigating the impact of near-term margin headwinds from accelerating cost inflation and supply chain constraints.

 

Commenting on the performance, CEO, Paul Waterman said,

"We have delivered a strong third quarter performance, have good trading momentum and are taking proactive steps to mitigate both rising inflation and global supply chain challenges. The delivery of our strategy, alongside a continued post COVID-19 demand recovery, is expected to drive a material, multi-year performance improvement, underpin the delivery of our medium-term Group financial objectives and generate significant shareholder value."

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUBRBRAKURUAA
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.